Comparative Pharmacology
Head-to-head clinical analysis: PREVACID NAPRAPAC 250 COPACKAGED versus ZEGERID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID NAPRAPAC 250 COPACKAGED versus ZEGERID.
PREVACID NAPRAPAC 250 (COPACKAGED) vs ZEGERID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lansoprazole: Proton pump inhibitor that irreversibly inhibits H+/K+ ATPase in gastric parietal cells, reducing gastric acid secretion. Naproxen: Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
Lansoprazole 15 mg plus naproxen 250 mg orally twice daily.
20 mg or 40 mg orally once daily before a meal.
None Documented
None Documented
Naproxen: 12-17 hours (terminal), allows twice-daily dosing. Lansoprazole: 1-2 hours (terminal), but acid suppression persists due to accumulation in parietal cells.
1.0–1.5 hours in plasma; however, the pharmacodynamic half-life is longer due to irreversible inhibition of H+/K+-ATPase; drug effect persists for 24 hours after single dose.
Naproxen: Renal (95% as unchanged drug and metabolites, primarily 6-O-desmethyl naproxen), fecal (<5%). Lansoprazole: Renal (20% as metabolites), fecal (80% as metabolites).
Approximately 82% renal (as metabolites), 18% fecal (via bile); less than 1% unchanged in urine.
Category C
Category C
Proton Pump Inhibitor/NSAID Combination
Proton Pump Inhibitor